Literature DB >> 28391298

Adjuvant nitrosoureas: will they ever go away?

Jan C Buckner1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28391298      PMCID： PMC5464063          DOI： 10.1093/neuonc/now268

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

1.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Authors:  Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran
Journal:  N Engl J Med       Date:  2016-04-07       Impact factor: 91.245

2.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Authors:  Andrew B Lassman; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Katherine S Panageas
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

3.  Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Authors:  Susan Chang; Peixin Zhang; J Gregory Cairncross; Mark R Gilbert; Jean-Paul Bahary; Carol A Dolinskas; Arnab Chakravarti; Kenneth D Aldape; Erica H Bell; David Schiff; Kurt Jaeckle; Paul D Brown; Geoffrey R Barger; Maria Werner-Wasik; Helen Shih; David Brachman; Marta Penas-Prado; H Ian Robins; Karl Belanger; Christopher Schultz; Grant Hunter; Minesh Mehta
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

4.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

5.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Authors:  Martin J van den Bent; Alba A Brandes; Martin J B Taphoorn; Johan M Kros; Mathilde C M Kouwenhoven; Jean-Yves Delattre; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; László Sipos; Roelien H Enting; Pim J French; Winand N M Dinjens; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia; Khê Hoang-Xuan
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Authors:  J Gregory Cairncross; Meihua Wang; Robert B Jenkins; Edward G Shaw; Caterina Giannini; David G Brachman; Jan C Buckner; Karen L Fink; Luis Souhami; Normand J Laperriere; Jason T Huse; Minesh P Mehta; Walter J Curran
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

7.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.